ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update [TheStreet.com]
ZyVersa Therapeutics, Inc. (ZVSA)
Company Research
Source: TheStreet.com
LIGHTHOUSE POINT, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (OTCQB: ZVSA), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, reports financial results for full year ending December 31, 2025, and provides business update. “The next 18 months are poised to be transformative for ZyVersa,” stated Stephen C. Glover, ZyVersa's Co-founder, Chairman, CEO, and President. “We are nearing completion of our preclinical program for Inflammasome ASC Inhibitor IC 100, with plans to file an IND in Q4-2026, followed by initiation of a Phase 1 trial in overweight healthy subjects at risk of cardiometabolic conditions. The SAD Phase 1 read-out is expected in Q1-2027. The Phase 1 trial will be supported by a preclinical study to be initiated in Q2-2026 in a diet-induced obesity mouse model, which develops cardiometabolic conditions. A preliminary read-out w
Show less
Read more
Impact Snapshot
Event Time:
ZVSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVSA alerts
High impacting ZyVersa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVSA
Sec Filings
- 3/31/26 - Form 10-K
- 3/5/26 - Form 8-K
- ZVSA's page on the SEC website